Skip to content
MMJ Gazette
  Monday 4 August 2025
  • About
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Authors
  • Home
  • News
  • CBD
  • Cannabis
  • Drugs
  • Marijuana
  • Tobacco
  • Law
Trending
August 3, 2025Cannabis Dispensaries Rethink Retail: Design That Sells, Not Just Serves August 2, 2025Legal Weed’s Tax Nightmare: How Cannabis Firms Are Pushing Back Against 280E August 2, 2025Kentucky Gears Up for First Legal Medical Marijuana Sales by Autumn July 31, 2025Hemp THC Ban Pulled from Senate Bill After McConnell–Paul Face-Off July 30, 2025Oklahoma’s Marijuana Legalisation Fight Is Back—And It’s Getting Personal July 30, 2025Starting a Cannabis Business? Here’s What You Really Need to Know First July 29, 2025New York’s Legal Weed Market Nears $1.5 Billion, But How Many Shops Can It Really Handle? July 29, 2025Texas Lawmaker Pushes Cannabis Legalisation Bill During Heated Hemp Debate July 28, 2025Cannabis Shops Are Getting a Makeover – and Sales Are Going Up July 26, 2025State Attorneys General Push Congress to Fix Outdated Marijuana Banking Laws
MMJ Gazette
MMJ Gazette
  • About
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Authors
MMJ Gazette
  Marijuana  Pro-Marijuana Doctors Challenge DEA in Court, Demand Fair Rescheduling Process
MarijuanaNews

Pro-Marijuana Doctors Challenge DEA in Court, Demand Fair Rescheduling Process

Lars BeckersLars Beckers—February 20, 20250
FacebookTwitterPinterestLinkedInTumblrRedditVKWhatsAppEmail

A group of doctors and researchers is taking the U.S. Drug Enforcement Administration (DEA) to court, arguing that the agency has mishandled the process of rescheduling marijuana. The legal challenge, filed by the Doctors for Drug Policy Reform (DDPR), aims to force the DEA to revisit key steps in determining whether cannabis should be moved from Schedule 1 to Schedule 3 under federal drug law.

Their complaint? A process they say is opaque, biased, and in violation of federal law.

Why the Doctors Are Fighting Back

The DEA has made it clear: marijuana’s legal status won’t change without a formal hearing. That hearing, initially planned for January 21, was suddenly put on hold, indefinitely delaying any progress. The decision left pro-rescheduling doctors, including DDPR leader Dr. Bryon Adinoff, frustrated and shut out.

  • The DEA denied 138 parties, including DDPR, the opportunity to participate in the hearing.
  • Despite the Justice Department’s proposal to move cannabis to Schedule 3 last year, the DEA refused to act without further review.
  • Former DEA Administrator Anne Milgram made it clear: no changes before the 2024 election, which President Joe Biden lost.

With the DEA fully controlling the process and showing no urgency, frustrated advocates see the courts as their only remaining option.

The Courtroom Becomes the Battlefield

The petition filed in the U.S. Court of Appeals for the D.C. Circuit challenges the DEA’s authority to keep the process stalled. According to federal law, courts can intervene if an agency’s actions are found to be “arbitrary, capricious, or otherwise contrary to law.” That’s exactly what the DDPR claims is happening.

The cannabis industry had hoped the new administration under Donald Trump would take a different stance on marijuana reform. But so far, Trump’s nominations for the Justice Department and DEA have not indicated any shift in federal cannabis policy.

This means the legal fight could be the only way forward.

Could This Lawsuit Force the DEA’s Hand?

The federal court’s decision in this case could have major implications for cannabis regulation. If the judges agree with the DDPR:

  • The DEA could be forced to restart the rescheduling process, this time with greater transparency.
  • Doctors and researchers who were previously shut out could get a chance to present their case.
  • It could put pressure on the Biden administration to push the DEA into action before leaving office.

On the other hand, if the court rules in favor of the DEA, the process could remain indefinitely stalled, leaving marijuana in its current Schedule 1 status—alongside heroin and LSD—for the foreseeable future.

Industry Stuck in Limbo as Rescheduling Battle Drags On

For businesses, researchers, and patients relying on medical marijuana, the continued uncertainty is proving costly.

Moving cannabis to Schedule 3 would bring significant changes:

  • It could reduce federal tax burdens on cannabis businesses.
  • More scientific research could be conducted without DEA restrictions.
  • Doctors and pharmacists would have clearer guidelines on prescribing cannabis-based treatments.

But with no clear timeline on when—or if—the rescheduling process will move forward, the industry remains in limbo.

What Happens Next?

All eyes are now on the D.C. Circuit Court of Appeals to see whether judges will intervene and force the DEA to redo the process.

Until then, marijuana reform remains at the mercy of bureaucratic delays, political maneuvering, and legal battles—with no end in sight.

FacebookTwitterPinterestLinkedInTumblrRedditVKWhatsAppEmail

Lars Beckers

Lars Beckers is a distinguished senior content writer at MMJ Gazette, bringing a wealth of experience and expertise to the realm of medical marijuana and cannabis-related content. With a deep understanding of the industry and a passion for sharing knowledge, Lars's articles offer readers comprehensive insights and engaging narratives in the dynamic world of cannabis. Known for his meticulous research, clarity of expression, and commitment to delivering high-quality content, Lars brings a seasoned perspective to his work, educating and informing audiences on the latest trends and developments in the field.

South Dakota Lawmaker’s Bid to Overturn Medical Cannabis Law Fails in Committee
Want Cannabis Customers to Return? A Retail Designer Shares Key Insights
Related posts
  • Related posts
  • More from author
Cannabis

Cannabis Dispensaries Rethink Retail: Design That Sells, Not Just Serves

August 3, 20250
Marijuana

Legal Weed’s Tax Nightmare: How Cannabis Firms Are Pushing Back Against 280E

August 2, 20250
Marijuana

Kentucky Gears Up for First Legal Medical Marijuana Sales by Autumn

August 2, 20250
Load more
Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SEARCH
PROMOTIONS
RECENT POSTS
  • Cannabis Dispensaries Rethink Retail: Design That Sells, Not Just Serves
  • Legal Weed’s Tax Nightmare: How Cannabis Firms Are Pushing Back Against 280E
  • Kentucky Gears Up for First Legal Medical Marijuana Sales by Autumn
  • Hemp THC Ban Pulled from Senate Bill After McConnell–Paul Face-Off
  • Oklahoma’s Marijuana Legalisation Fight Is Back—And It’s Getting Personal
  • Starting a Cannabis Business? Here’s What You Really Need to Know First
  • New York’s Legal Weed Market Nears $1.5 Billion, But How Many Shops Can It Really Handle?
  • Texas Lawmaker Pushes Cannabis Legalisation Bill During Heated Hemp Debate
  • Cannabis Shops Are Getting a Makeover – and Sales Are Going Up
  • State Attorneys General Push Congress to Fix Outdated Marijuana Banking Laws
    © MMJ Gazette. 2024
    • About
    • Contact Us
    • Privacy Policy
    • Terms and Conditions
    • Authors